Drug intelligence / Profile preview

retinal ganglion cell precursor cell therapy

Development stage: Preclinical
Lead developer: InGel Therapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Hydrogel Systems → Drug Delivery Systems
Administration: Ophthalmic

Overview

InGel Therapeutics is developing a retinal ganglion cell (RGC) precursor cell therapy for the treatment of retinal degenerative diseases. This engineered cell therapy utilizes precursor cells that are lineage-committed to becoming RGCs but retain proliferative capacity. The cells are delivered using a proprietary, biodegradable, vitreous-mimicking hydrogel system designed to protect the cells from mechanical stress during injection and support their survival and integration within the host retina. The therapy aims to restore visual function by replacing lost or damaged RGCs in conditions such as glaucoma, dry age-related macular degeneration (AMD), and retinitis pigmentosa. The program is currently in preclinical development and is part of a broader regenerative platform that also includes photoreceptor precursor therapies.

Other names: RGC precursor cell therapyInGel RGC therapyretinal ganglion cell precursor cells

Beyond the preview

Go deeper on retinal ganglion cell precursor cell therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on retinal ganglion cell precursor cell therapy.

Explore the full profile